A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Researchers conducting this study hope to learn about the safety and effectiveness of combining two study drugs, relacorilant and enzalutamide, plus androgen deprivation therapy (ADT), also known as hormone therapy. This study is for individuals who have been diagnosed with advanced, high-risk prostate cancer and standard therapies available to treat your disease have not been effective. Participation in this research will last about 3 years and 9 months.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony histologicznie lub cytologicznie rak gruczołu krokowego (adenocarcinoma)
- •Choroba zlokalizowana bez przerzutów do odległych narządów
- •Wysoka lub bardzo wysoka grupa ryzyka (określona wielkością guza, stopniem zaawansowania lub poziomem PSA powyżej 20)
- •Stan zdrowia pozwalający na uczestnictwo w badaniu (skala ECOG ≤1)
- •Prawidłowe funkcjonowanie wątroby, nerek i szpiku kostnego (potwierdzone badaniami krwi)
- •Gotowość do codziennego monitorowania poziomu cukru we krwi (szczególnie dla pacjentów z cukrzycą)
- •Zdolność do zrozumienia badania i podpisania zgody
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 31, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (4)
University of Chicago Comprehensive Cancer Center
Chicago, United States
Endeavor Health
Evanston, United States
Oregon Health & Science University
Portland, United States
University of Texas Southwestern Medical Center
Dallas, United States
Trial contact
Cancer Trials
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.